In Response to: “Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?”

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thoracic oncology 2022-02, Vol.17 (2), p.e12-e14
Hauptverfasser:	Thomas, Nicholas J., Myall, Nathaniel J., Sun, Fangdi, Patil, Tejas, Mushtaq, Rao, Yu, Chandler, Sinha, Sumi, Pollom, Erqi L., Nagpal, Seema, Camidge, D. Ross, Rusthoven, Chad G., Braunstein, Steve E., Wakelee, Heather A., McCoach, Caroline E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Brain Neoplasms - radiotherapy Carcinoma, Non-Small-Cell Lung - radiotherapy ErbB Receptors - genetics Humans Lung Neoplasms - radiotherapy Receptor Protein-Tyrosine Kinases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	e14
container_issue	2
container_start_page	e12
container_title	Journal of thoracic oncology
container_volume	17
creator	Thomas, Nicholas J. Myall, Nathaniel J. Sun, Fangdi Patil, Tejas Mushtaq, Rao Yu, Chandler Sinha, Sumi Pollom, Erqi L. Nagpal, Seema Camidge, D. Ross Rusthoven, Chad G. Braunstein, Steve E. Wakelee, Heather A. McCoach, Caroline E.
description
doi_str_mv	10.1016/j.jtho.2021.11.017
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2622659443</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1556086421033918</els_id><sourcerecordid>2622659443</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-3c2db1c80b84288758663eed240a0982ca4c5a6cb6c1868b62fa66f71fe6916a3</originalsourceid><addsrcrecordid>eNp9kcFuEzEURUcIREvhB1ggL9nMYHs8jlMhoTBKS0WgKIC6tDz2G-JoYk9tJ1J3_Qs28HP9EhwlsER6kt_i3GtbpyheElwRTPibdbVOK19RTElFSIXJ5FFxSpqGl6QW-PFxx4Kzk-JZjGuMWYOZeFqc1A2eMEqnp8XPK4eWEEfvIqDkz9HD_a_Wb0YVrPuBZsbYZL1DvkdLZaxPKwhqvEPWofnlxbJEyhk0W3wsv_iYyR2gz1_bRYtubFqh90Fl7hMkFfNAPEezAOgG0Hynhq1K-xtyIboek92oAc2dGb116d3D_e_nxZNeDRFeHM-z4vvF_Fv7oVxcX161s0Wp64akstbUdEQL3AlGhZg0gvMawFCGFZ4KqhXTjeK645oILjpOe8V5PyE98Cnhqj4rXh96x-BvtxCT3NioYRiUA7-NknJKeTNlrM4oPaA6-BgD9HIM-d3hThIs90LkWu6FyL0QSYjMQnLo1bF_223A_Iv8NZCBtwcA8i93FoKM2oLTYGwAnaTx9n_9fwDpOJ2O</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2622659443</pqid></control><display><type>article</type><title>In Response to: “Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?”</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Thomas, Nicholas J. ; Myall, Nathaniel J. ; Sun, Fangdi ; Patil, Tejas ; Mushtaq, Rao ; Yu, Chandler ; Sinha, Sumi ; Pollom, Erqi L. ; Nagpal, Seema ; Camidge, D. Ross ; Rusthoven, Chad G. ; Braunstein, Steve E. ; Wakelee, Heather A. ; McCoach, Caroline E.</creator><creatorcontrib>Thomas, Nicholas J. ; Myall, Nathaniel J. ; Sun, Fangdi ; Patil, Tejas ; Mushtaq, Rao ; Yu, Chandler ; Sinha, Sumi ; Pollom, Erqi L. ; Nagpal, Seema ; Camidge, D. Ross ; Rusthoven, Chad G. ; Braunstein, Steve E. ; Wakelee, Heather A. ; McCoach, Caroline E.</creatorcontrib><identifier>ISSN: 1556-0864</identifier><identifier>EISSN: 1556-1380</identifier><identifier>DOI: 10.1016/j.jtho.2021.11.017</identifier><identifier>PMID: 35074229</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Brain Neoplasms - radiotherapy ; Carcinoma, Non-Small-Cell Lung - radiotherapy ; ErbB Receptors - genetics ; Humans ; Lung Neoplasms - radiotherapy ; Receptor Protein-Tyrosine Kinases</subject><ispartof>Journal of thoracic oncology, 2022-02, Vol.17 (2), p.e12-e14</ispartof><rights>2021 International Association for the Study of Lung Cancer</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c351t-3c2db1c80b84288758663eed240a0982ca4c5a6cb6c1868b62fa66f71fe6916a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35074229$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thomas, Nicholas J.</creatorcontrib><creatorcontrib>Myall, Nathaniel J.</creatorcontrib><creatorcontrib>Sun, Fangdi</creatorcontrib><creatorcontrib>Patil, Tejas</creatorcontrib><creatorcontrib>Mushtaq, Rao</creatorcontrib><creatorcontrib>Yu, Chandler</creatorcontrib><creatorcontrib>Sinha, Sumi</creatorcontrib><creatorcontrib>Pollom, Erqi L.</creatorcontrib><creatorcontrib>Nagpal, Seema</creatorcontrib><creatorcontrib>Camidge, D. Ross</creatorcontrib><creatorcontrib>Rusthoven, Chad G.</creatorcontrib><creatorcontrib>Braunstein, Steve E.</creatorcontrib><creatorcontrib>Wakelee, Heather A.</creatorcontrib><creatorcontrib>McCoach, Caroline E.</creatorcontrib><title>In Response to: “Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?”</title><title>Journal of thoracic oncology</title><addtitle>J Thorac Oncol</addtitle><subject>Brain Neoplasms - radiotherapy</subject><subject>Carcinoma, Non-Small-Cell Lung - radiotherapy</subject><subject>ErbB Receptors - genetics</subject><subject>Humans</subject><subject>Lung Neoplasms - radiotherapy</subject><subject>Receptor Protein-Tyrosine Kinases</subject><issn>1556-0864</issn><issn>1556-1380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFuEzEURUcIREvhB1ggL9nMYHs8jlMhoTBKS0WgKIC6tDz2G-JoYk9tJ1J3_Qs28HP9EhwlsER6kt_i3GtbpyheElwRTPibdbVOK19RTElFSIXJ5FFxSpqGl6QW-PFxx4Kzk-JZjGuMWYOZeFqc1A2eMEqnp8XPK4eWEEfvIqDkz9HD_a_Wb0YVrPuBZsbYZL1DvkdLZaxPKwhqvEPWofnlxbJEyhk0W3wsv_iYyR2gz1_bRYtubFqh90Fl7hMkFfNAPEezAOgG0Hynhq1K-xtyIboek92oAc2dGb116d3D_e_nxZNeDRFeHM-z4vvF_Fv7oVxcX161s0Wp64akstbUdEQL3AlGhZg0gvMawFCGFZ4KqhXTjeK645oILjpOe8V5PyE98Cnhqj4rXh96x-BvtxCT3NioYRiUA7-NknJKeTNlrM4oPaA6-BgD9HIM-d3hThIs90LkWu6FyL0QSYjMQnLo1bF_223A_Iv8NZCBtwcA8i93FoKM2oLTYGwAnaTx9n_9fwDpOJ2O</recordid><startdate>202202</startdate><enddate>202202</enddate><creator>Thomas, Nicholas J.</creator><creator>Myall, Nathaniel J.</creator><creator>Sun, Fangdi</creator><creator>Patil, Tejas</creator><creator>Mushtaq, Rao</creator><creator>Yu, Chandler</creator><creator>Sinha, Sumi</creator><creator>Pollom, Erqi L.</creator><creator>Nagpal, Seema</creator><creator>Camidge, D. Ross</creator><creator>Rusthoven, Chad G.</creator><creator>Braunstein, Steve E.</creator><creator>Wakelee, Heather A.</creator><creator>McCoach, Caroline E.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202202</creationdate><title>In Response to: “Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?”</title><author>Thomas, Nicholas J. ; Myall, Nathaniel J. ; Sun, Fangdi ; Patil, Tejas ; Mushtaq, Rao ; Yu, Chandler ; Sinha, Sumi ; Pollom, Erqi L. ; Nagpal, Seema ; Camidge, D. Ross ; Rusthoven, Chad G. ; Braunstein, Steve E. ; Wakelee, Heather A. ; McCoach, Caroline E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-3c2db1c80b84288758663eed240a0982ca4c5a6cb6c1868b62fa66f71fe6916a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Brain Neoplasms - radiotherapy</topic><topic>Carcinoma, Non-Small-Cell Lung - radiotherapy</topic><topic>ErbB Receptors - genetics</topic><topic>Humans</topic><topic>Lung Neoplasms - radiotherapy</topic><topic>Receptor Protein-Tyrosine Kinases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thomas, Nicholas J.</creatorcontrib><creatorcontrib>Myall, Nathaniel J.</creatorcontrib><creatorcontrib>Sun, Fangdi</creatorcontrib><creatorcontrib>Patil, Tejas</creatorcontrib><creatorcontrib>Mushtaq, Rao</creatorcontrib><creatorcontrib>Yu, Chandler</creatorcontrib><creatorcontrib>Sinha, Sumi</creatorcontrib><creatorcontrib>Pollom, Erqi L.</creatorcontrib><creatorcontrib>Nagpal, Seema</creatorcontrib><creatorcontrib>Camidge, D. Ross</creatorcontrib><creatorcontrib>Rusthoven, Chad G.</creatorcontrib><creatorcontrib>Braunstein, Steve E.</creatorcontrib><creatorcontrib>Wakelee, Heather A.</creatorcontrib><creatorcontrib>McCoach, Caroline E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thoracic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thomas, Nicholas J.</au><au>Myall, Nathaniel J.</au><au>Sun, Fangdi</au><au>Patil, Tejas</au><au>Mushtaq, Rao</au><au>Yu, Chandler</au><au>Sinha, Sumi</au><au>Pollom, Erqi L.</au><au>Nagpal, Seema</au><au>Camidge, D. Ross</au><au>Rusthoven, Chad G.</au><au>Braunstein, Steve E.</au><au>Wakelee, Heather A.</au><au>McCoach, Caroline E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Response to: “Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?”</atitle><jtitle>Journal of thoracic oncology</jtitle><addtitle>J Thorac Oncol</addtitle><date>2022-02</date><risdate>2022</risdate><volume>17</volume><issue>2</issue><spage>e12</spage><epage>e14</epage><pages>e12-e14</pages><issn>1556-0864</issn><eissn>1556-1380</eissn><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35074229</pmid><doi>10.1016/j.jtho.2021.11.017</doi><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 1556-0864
ispartof	Journal of thoracic oncology, 2022-02, Vol.17 (2), p.e12-e14
issn	1556-0864 1556-1380
language	eng
recordid	cdi_proquest_miscellaneous_2622659443
source	MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects	Brain Neoplasms - radiotherapy Carcinoma, Non-Small-Cell Lung - radiotherapy ErbB Receptors - genetics Humans Lung Neoplasms - radiotherapy Receptor Protein-Tyrosine Kinases
title	In Response to: “Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?”
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T00%3A33%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Response%20to:%20%E2%80%9CComparing%20Addition%20of%20Radiotherapy%20in%20EGFR-%20and%20ALK-Positive%20NSCLC%20With%20Brain%20Metastases:%20Are%20We%20Evaluating%20the%20Optimal%20Endpoint?%E2%80%9D&rft.jtitle=Journal%20of%20thoracic%20oncology&rft.au=Thomas,%20Nicholas%20J.&rft.date=2022-02&rft.volume=17&rft.issue=2&rft.spage=e12&rft.epage=e14&rft.pages=e12-e14&rft.issn=1556-0864&rft.eissn=1556-1380&rft_id=info:doi/10.1016/j.jtho.2021.11.017&rft_dat=%3Cproquest_cross%3E2622659443%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2622659443&rft_id=info:pmid/35074229&rft_els_id=S1556086421033918&rfr_iscdi=true